GKL-006Allo not checked
Beijing Gene Key Life Technology Co., Ltd · GKL-006RTU
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Allogeneic invariant natural killer T (iNKT) cells administered by intravenous infusion once every two weeks for up to 11 doses. Dose escalation from (3.0±0.9)×10\^8 cells/m2 to (9.0±2.7)×10\^8 cells/m2 per the 3+3 dose-escalation design.”In the company’s words, NCT07915544 on ClinicalTrials.gov
- Tested for
- ARDS (Acute Respiratory Distress Syndrome), Ankylosing Spondylitis, Solid Tumor Malignancies
- Main trialPhase 1/2
- “This is a Phase I/II, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of GKL-006RTU injection in participants with moderate to severe Acute Respiratory Distress Syndrome (ARDS). The study consists of two parts: Phase I is a single-arm, open-label study. Eligible participants will receive a single intravenous infusion of GKL-006RTU injection (1 bag or 3 bags, containing approximately 5.0±0.5×10\^8 invariant natural killer T (iNKT) cells per bag) in addition to standard background treatment. The primary objective of this phase is to assess the safety…”In the company’s words, NCT07706855 on ClinicalTrials.gov
- Other names
- Allogeneic iNKT Cell Therapy · GKL-006RTU
Other drugs for ARDS (Acute Respiratory Distress Syndrome)
- ParidiprubartPPD Development, LP · Phase 2
- VilobelimabInflaRx GmbH · Phase 2
- AtibuclimabImplicit Bioscience · Phase 2
- HT31-1HTIC, Inc · Phase 1
Coming up3
- 30 Mar 2028Phase 1 trial completes · ClinicalTrials.gov
- 30 Sep 2028Phase 1 trial completes · ClinicalTrials.gov
- 30 Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 30 Dec 2028 | Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) | |
| Phase 1Not yet recruiting | 30 Mar 2028 | A Study of GKL-006Allo Injection in Patients With Ankylosing Spondylitis | |
| Phase 1Not yet recruiting | 30 Sep 2028 | GKL-006Allo Injection in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026